Symbol
| PNPLA2
| contributors: mct/npt/pgu - updated : 23-06-2015
|
HGNC name
| patatin-like phospholipase domain containing 2
|
HGNC id
| 30802
|
corresponding disease(s)
|
NLSDM
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
constitutional
|  
|  
| --over
|  
|
decreases intracellular triglyceride levels | constitutional
|  
|  
|  
| gain of function
|
by fasting in adipose tissue | constitutional
|  
|  
| --over
|  
|
is sufficient to alter myocardial energy metabolism and improve cardiac function | constitutional
|  
|  
| --other
|  
|
altered PNPLA2 and LIPE expression in skeletal muscle could promote diacylglycerol accumulation and disrupt insulin signaling and action | constitutional
|  
|  
| --over
|  
|
LIPE or PNPLA2 overexpression resulted in increased triglyceride-specific hydrolase capacity, but only PNPLA2 overexpression increased whole cell lipolysis | |
Variant & Polymorphism
|
| |
Candidate gene
Marker
Therapy target
|
System | Type | Disorder | Pubmed |
cancer | | | |
pharmacological inhibition of lipases LIPE and PNPLA2) may represent a powerful strategy to avoid the devastating condition of cachexia in response to cancer or other chronic diseases |
| | | |
| Atgl-/- mice were protected from tumor-associated skeletal muscle loss | |
Mice deficient for adipose triglyceride lipase (ATGL-ko) exhibit defective lipolysis and accumulate TG in adipose tissue and muscle |